The Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE in Prostate Cancer Biostatistics and Computational Biology Core collaborates and provides consultation on all research activities within the SPORE, including SPORE Projects, Developmental Projects, Projects of the Career Development Awardees, and other SPORE Cores, to ensure the highest standards of scientific rigor in areas of study design, data management and integrity, and data analysis and interpretation.
The specific aims are to: 1. Provide biostatistical and computational biology expertise for the planning and design, conduct, analysis, and reporting of laboratory, genomic, animal, translational, clinical (including associated correlative studies), and epidemiological studies for SPORE projects. Developmental Projects, Projects of the Career Development Awardees, and other SPORE Cores. 2. Provide consultation on all issues of data management and integrity, including data collection, storage, transfer and quality assurance, on statistical and computational biology software and programs, and on coordination of laboratory results with parameters and outcomes from clinical studies or clinical/translational research databases. 3. Provide short-term biostatistics and computational biology consulting to the entire group of SPORE researchers.

Public Health Relevance

The Biostatistics and Computational Biology Core is an integral part of research activities within the DF/HCC SPORE in Prostate Cancer. The Core's objective is to ensure the highest standards of scientific rigor in areas of study design, data integrity, and data analysis and interpretation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090381-12
Application #
8764826
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215
Preston, Mark A; Batista, Julie L; Wilson, Kathryn M et al. (2016) Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol 34:2705-11
Sinnott, Jennifer A; Peisch, Sam; Tyekucheva, Svitlana et al. (2016) Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res :
Yang, Meng; Zu, Ke; Mucci, Lorelei A et al. (2016) Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control 27:1043-7
Thorgeirsson, Tryggvi; Jordahl, Kristina M; Flavin, Richard et al. (2016) Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. Carcinogenesis 37:262-8
Kelly, Rachel S; Vander Heiden, Matthew G; Giovannucci, Edward et al. (2016) Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev 25:887-906
Gerrin, Sean J; Sowalsky, Adam G; Balk, Steven P et al. (2016) Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. Prostate 76:1227-36
Liu, Xiaming; Han, Weiwei; Gulla, Sarah et al. (2016) Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget 7:1754-64
Ahearn, Thomas U; Tchrakian, Nairi; Wilson, Kathryn M et al. (2016) Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. J Clin Endocrinol Metab 101:2520-7
Li, Zhenfei; Alyamani, Mohammad; Li, Jianneng et al. (2016) Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature 533:547-51
Xie, Wanling; Yang, Ming; Chan, June et al. (2016) Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. Prostate 76:691-9

Showing the most recent 10 out of 217 publications